NEXTCURE INC (NXTC) Fundamental Analysis & Valuation

NASDAQ:NXTC • US65343E2072

12.39 USD
-0.37 (-2.9%)
Last: Mar 6, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NXTC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NXTC. NXTC was compared to 520 industry peers in the Biotechnology industry. While NXTC seems to be doing ok healthwise, there are quite some concerns on its profitability. NXTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. NXTC Profitability Analysis

1.1 Basic Checks

  • NXTC had negative earnings in the past year.
  • In the past year NXTC has reported a negative cash flow from operations.
  • NXTC had negative earnings in each of the past 5 years.
  • In the past 5 years NXTC always reported negative operating cash flow.
NXTC Yearly Net Income VS EBIT VS OCF VS FCFNXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • NXTC has a worse Return On Assets (-146.44%) than 83.46% of its industry peers.
  • With a Return On Equity value of -245.33%, NXTC is not doing good in the industry: 70.77% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -146.44%
ROE -245.33%
ROIC N/A
ROA(3y)-53.01%
ROA(5y)-39.92%
ROE(3y)-61.74%
ROE(5y)-45.48%
ROIC(3y)N/A
ROIC(5y)N/A
NXTC Yearly ROA, ROE, ROICNXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • NXTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXTC Yearly Profit, Operating, Gross MarginsNXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NXTC Health Analysis

2.1 Basic Checks

  • NXTC has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, NXTC has more shares outstanding
  • NXTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NXTC Yearly Shares OutstandingNXTC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
NXTC Yearly Total Debt VS Total AssetsNXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • NXTC has an Altman-Z score of -18.11. This is a bad value and indicates that NXTC is not financially healthy and even has some risk of bankruptcy.
  • NXTC has a Altman-Z score of -18.11. This is amonst the worse of the industry: NXTC underperforms 81.35% of its industry peers.
  • NXTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.11
ROIC/WACCN/A
WACCN/A
NXTC Yearly LT Debt VS Equity VS FCFNXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • NXTC has a Current Ratio of 2.97. This indicates that NXTC is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.97, NXTC is not doing good in the industry: 64.04% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.97 indicates that NXTC has no problem at all paying its short term obligations.
  • NXTC's Quick ratio of 2.97 is on the low side compared to the rest of the industry. NXTC is outperformed by 62.31% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
NXTC Yearly Current Assets VS Current LiabilitesNXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NXTC Growth Analysis

3.1 Past

  • NXTC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.87%.
EPS 1Y (TTM)3.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NXTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.72% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.73%
EPS Next 2Y28.33%
EPS Next 3Y22.78%
EPS Next 5Y13.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NXTC Yearly Revenue VS EstimatesNXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 10M 20M 30M 40M
NXTC Yearly EPS VS EstimatesNXTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. NXTC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NXTC. In the last year negative earnings were reported.
  • Also next year NXTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXTC Price Earnings VS Forward Price EarningsNXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXTC Per share dataNXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NXTC's earnings are expected to grow with 22.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.33%
EPS Next 3Y22.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NXTC Dividend Analysis

5.1 Amount

  • NXTC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NXTC Fundamentals: All Metrics, Ratios and Statistics

NEXTCURE INC

NASDAQ:NXTC (3/6/2026, 8:00:02 PM)

12.39

-0.37 (-2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04
Earnings (Next)04-29
Inst Owners32.85%
Inst Owner Change120.19%
Ins Owners1.53%
Ins Owner Change0%
Market Cap33.21M
Revenue(TTM)N/A
Net Income(TTM)-58.01M
Analysts84.44
Price Target18.02 (45.44%)
Short Float %2.88%
Short Ratio1.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-59.55%
Min EPS beat(2)-139.84%
Max EPS beat(2)20.75%
EPS beat(4)2
Avg EPS beat(4)-33.67%
Min EPS beat(4)-139.84%
Max EPS beat(4)20.75%
EPS beat(8)3
Avg EPS beat(8)-27.3%
EPS beat(12)6
Avg EPS beat(12)-15.42%
EPS beat(16)8
Avg EPS beat(16)-11.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25.18%
EPS NY rev (1m)0%
EPS NY rev (3m)10.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.4
EV/EBITDA N/A
EPS(TTM)-24.11
EYN/A
EPS(NY)-8.39
Fwd EYN/A
FCF(TTM)-18.25
FCFYN/A
OCF(TTM)-18.26
OCFYN/A
SpS0
BVpS8.82
TBVpS8.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.44%
ROE -245.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.01%
ROA(5y)-39.92%
ROE(3y)-61.74%
ROE(5y)-45.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -18.11
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)30.09%
Cap/Depr(5y)71.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.55%
EPS Next Y31.73%
EPS Next 2Y28.33%
EPS Next 3Y22.78%
EPS Next 5Y13.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.5%
OCF growth 3YN/A
OCF growth 5YN/A

NEXTCURE INC / NXTC FAQ

What is the ChartMill fundamental rating of NEXTCURE INC (NXTC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NXTC.


What is the valuation status of NEXTCURE INC (NXTC) stock?

ChartMill assigns a valuation rating of 1 / 10 to NEXTCURE INC (NXTC). This can be considered as Overvalued.


What is the profitability of NXTC stock?

NEXTCURE INC (NXTC) has a profitability rating of 0 / 10.


What is the financial health of NEXTCURE INC (NXTC) stock?

The financial health rating of NEXTCURE INC (NXTC) is 5 / 10.